Keith D. Dawkins, MD FRCP FACC
Keith D. Dawkins, MD, is Senior Vice President and Associate Chief Medical Officer to Boston Scientific Corporation.
DES Talk: Thoughts on Interventional Cardiology
The latest perspectives on interventional cardiology by Boston Scientific's leading doctors and scientists.
Comments on SYNTAX Trial
by Keith D. Dawkins, MD FRCP FACC
The SYNTAX Trial compares the roles of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) using drug-eluting stents in the contemporary management of left-main and three-vessel disease patients.
Dr. Dawkins discusses trial details as presented at the European Society of Cardiology Congress 2008 in Munich, Germany.
The safety and efficacy of the TAXUS® Express® Stent have not been established in patients with left main and/or multi-vessel disease.
About the Authors
Keith D. Dawkins, MD FRCP FACC
Keith D. Dawkins, MD, is Senior Vice President and Associate Chief Medical Officer to Boston Scientific Corporation.
